Capecitabine with weekly paclitaxel for advanced breast cancer: A phase I dose-finding trial

Oncology

Volumn 67, Issue 2, 2004, Pages 117-122

  Uhlmann, Catrina ^a   Ballabeni, Pierluigi ^b   Rijken, Natalie ^b   Brauchli, Peter ^b   Mingrone, Walter ^c   Rauch, Daniel ^d   Pestalozzi, Bernhard C ^e   Rochlitz, Christoph ^f   Aebi, Stefan ^a,g  

^a UNIVERSITY OF BERN   (Switzerland)

^b IBCSG Coordinating Center   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d Spital Thun   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

Advanced breast cancer; Capecitabine; Paclitaxel; Phase I trial

Indexed keywords

CAPECITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN METASTASIS; BREAST CANCER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LOW BACK PAIN; MAXIMUM TOLERATED DOSE; METASTASIS; NAIL DISEASE; NAUSEA; NEUROTOXICITY; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; SENSORY DYSFUNCTION; SKIN EXFOLIATION; SKIN TOXICITY; SUPRAVENTRICULAR TACHYCARDIA; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NAILS; PACLITAXEL; SKIN; SWITZERLAND; TREATMENT OUTCOME;

EID: 8344243084     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080997     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352:930-942.
3. Ellis MJ, Hayes DF, Lippman ME: Treatment of metastatic breast cancer; in Harris JR, Lippman ME, Morrow M, Osborne CK (eds): Diseases of the Breast, ed 2. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 749-797.
4. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-3460.
5. Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J: A randomized study of paclitaxel versus cyclophosphamide/ methotrexate/5-fluorouracil/ prednisone in previously untreated patients with advanced breast cancer: Preliminary results. Taxol Investigational Trials Group, Australia/ New Zealand. Semin Oncol 1997;24(5 suppl 17):S17-5-S17-9.
6. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L: Dosedense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-3361.
7. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-4223.
8. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
9. Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ, Osterwalder B, Verweij J, Twelves C: A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000;83:22-29.
10. Khoury P, Villalona-Calero M, Blum J, Diab S, Elledge R, Kraynak M, Moczygemba J, Kromelis P, Morales I, Brown C, Griffin T, Von Hoff D, Rowinsky E: Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:206a.
11. Meza LA, Amin B, Horsey M, Petralia SA, Szatrowski TP, Gradishar WJ: A phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001;19:70b.
12. Perez-Manga G, Constenla M, Guillem V, et al: Efficacy and safety of capecitabine (Xeloda) in combination with paclitaxel in patients with locally advanced or metastatic breast cancer: Preliminary results of a phase II study. Breast Cancer Res Treat 2000;64:124.
13. Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M, Tolino G, Lambiase A, Baldini A, Canavese G, Rosso R: Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann Oncol 2002;13:546-552.
14. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B: Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/ advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
15. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998;55:1091-1097.
16. Eda H, Fujimoto K, Watanabe S, Ishikawa T, Ohiwa T, Tatsuno K, Tanaka Y, Ishitsuka H: Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5)-deoxy-5-fluorouridine. Jpn J Cancer Res 1993;84:341-347.
17. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-1019.
18. Johnson DH, Paul D, Hande KR: Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Semin Oncol 1997;24:S22-S25.
19. Vredenburgh J, Fishman R, Coniglio D, Matters L, Elkordy M, Ross M, Hussein A, Rubin P, Gilbert C, Petros W, Peters WP: The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer. Am J Clin Oncol 1998;21:543-547.
20. Klaassen U, Wilke H, Harstrick A, Philippou Pari C, Strumberg D, Neumann K, Eberhardt W, Achterrath W, Lenaz L, Seeber S: Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the secondline treatment of metastatic breast cancer: Results of a phase II study. Ann Oncol 1998;9:45-50.
21. Nicholson B, Paul D, Shyr Y, Garrett M, Hande KR, Johnson DH: Paclitaxel/5-fluorouracil/ leucovorin in metastatic breast cancer: A Vanderbilt Cancer Center phase II trial. Semin Oncol 1997;24(4 suppl 11):S11-20-S11-23.
22. Simon R: Design and analysis of clinical trials; in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer. Principles and Practice of Oncology, ed 6. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 521-538.
23. Mackey JR, Tonkin K, Scarfe AG, Koski S, Smylie M, Au HJ, Bodnar D, Smith SW, Soulieres D: Final results of a phase II clinical trial of weekly docetaxel (T) in combination with capecitabine (X) in anthracycline pre-treated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003;22:42.
24. Spazzapan S, Crivellari D, Lombardi D, Scuderi C, Magri MD, Veronesi A, Gatti A: Nail toxicity related to weekly taxanes: An important issue requiring a change in common toxicity criteria grading? J Clin Oncol 2002;20: 4404-4405; author reply 4405.
25. Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD, Rowinsky EK: Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 1999;17:1915-1925.
26. Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK: A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol 2001;12:605-614.
27. Gradishar W, Meza L, Hill T, Chen Y-M, Varkey J, Amin B: Three-year results from a multicenter phase II study of Xeloda (capecitabine) plus paclitaxel in metastatic breast cancer. Breast Cancer Res Treat 2002;76:S90.
28. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-2823.
29. Elza-Brown K, Dees E, Wolff A, Carducci M, Donehower R: A phase I study of capecitabine and weekly paclitaxel in advanced solid tumors. Proc Am Soc Clin Oncol 2000;19:237a.
30. Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, Clinton S, Shah M, Stanek M, Monk P, Villalona-Calero MA: Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002;20:2616-2623.